Stockreport

Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical School

Axon Enterprise, Inc.  (AXON) 
Last axon enterprise, inc. earnings: 2/7 04:15 pm Check Earnings Report
US:NYSE Investor Relations: investors.axovant.com/investors/sec-filings
PDF Two novel programs for fatal pediatric diseases deepen Axovant’s neurological gene therapy pipelineAXO-AAV-GM1 expected to enter the clinic in first half 2019, with init [Read more]